A mitochondrial protein comes into focus
Researchers at Pennington Biomedical Research Center have identified Miro1 as a potential contributor to insulin resistance in type 2 diabetes, a finding that could open a new line of investigation for treatments aimed at improving blood-sugar control.
Miro1, formally known as Mitochondrial Rho GTPase 1, is found on the outer membrane of mitochondria. Those structures generate energy inside cells, and the research team focused on the protein’s role in skeletal muscle, a major tissue involved in responding to insulin.
According to the researchers, Miro1 levels were higher in the skeletal muscles of people with type 2 diabetes. Across laboratory cells, preclinical models and human participants, the team found evidence that a buildup of the protein impaired muscle responsiveness to insulin.
Why insulin response matters
Insulin resistance is a central feature of type 2 diabetes. When muscle and other tissues do not respond effectively to insulin, it becomes harder for the body to regulate blood sugar. The new work points to a possible molecular process within muscle cells that may be part of that loss of responsiveness.
The study did more than identify an association. In preclinical experiments, removing Miro1 restored muscles’ responsiveness to insulin, the researchers reported. That result supports the view that the protein may contribute directly to insulin resistance rather than merely changing alongside the disease.
The findings were published in Nature Communications. They do not establish a new treatment for people with diabetes, but they provide a specific target for researchers seeking to understand how insulin resistance develops and how it might be reduced.
Exercise and Miro1
The work also examined whether exercise affects Miro1 in people living with type 2 diabetes. In a randomized controlled trial, exercise lowered Miro1 levels in participants with the disease.
Physical activity is already known to improve insulin sensitivity, but the study offers a possible biological pathway that could help explain part of that benefit. The researchers suggest that reducing Miro1 may be one mechanism through which exercise improves the ability of muscle to respond to insulin.
That observation is particularly useful because it connects human results with the laboratory and preclinical findings. Elevated Miro1 was observed in human skeletal muscle, the protein’s effects were investigated in several experimental settings, and exercise was associated with lower levels in people with type 2 diabetes.
A research target, not a replacement for care
The study’s results should be viewed as an early-stage therapeutic opportunity. The evidence for restoring insulin response by removing Miro1 comes from preclinical models, while the human exercise findings show that the protein can be reduced in people with the disease. Additional work will be needed to determine whether directly targeting Miro1 can safely improve clinical outcomes.
Still, the research narrows attention to a previously less prominent protein at the interface of mitochondria, skeletal muscle and insulin action. That focus may help scientists test whether Miro1 can serve as a biomarker, a drug target, or both.
For now, the study adds mechanistic detail to an established public-health message: exercise can improve insulin sensitivity. It also raises the prospect that treatments inspired by exercise biology could one day complement existing approaches to managing type 2 diabetes.
What the study shows
- Miro1 was found at higher levels in skeletal muscle from people with type 2 diabetes.
- Its buildup was associated with impaired muscle response to insulin.
- Removing Miro1 restored insulin responsiveness in preclinical experiments.
- Exercise lowered Miro1 levels in a randomized controlled trial involving people with diabetes.
This article is based on reporting by Science Daily. Read the original article.
Originally published on sciencedaily.com
